Table 1 Demographics and extension study baseline characteristics (full analysis set).

From: Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Demographic variable

Adolescent study

(N = 119)

Adult study

(N = 148)

Age (years)

15.2 (1.8)

26.6 (6.9)

  Range

12–19

18–45

Sex, male, n (%)

106 (89.1)

138 (93.2)

Race, n (%)

  Caucasian

110 (92.4)

142 (95.9)

  Black

2 (1.7)

2 (1.4)

  Asian

3 (2.5)

0

  Native American

1 (0.8)

0

  Other

3 (2.5)

4 (2.7)

Weight (kg)

64.5 (16.9)

80.9 (17.9)

  Range

34.8–122.5

41.4–131.0

ABC-CFX total score

49.8 (29.0)

43.4 (26.8)

  Range

6 to 146

2 to 134

CGI-S score, n (%)

  2 (Borderline mentally ill)

0

0

  3 (Mildly ill)

5 (4.2)

3 (2.0)

  4 (Moderately ill)

54 (45.4)

64 (43.2)

  5 (Markedly ill)

43 (36.1)

55 (37.2)

  6 (Severely ill)

17 (14.3)

22 (14.9)

  7 (Among the most extremely ill)

0

4 (2.7)

IQ score

41.0 (9.3)

47.0 (7.0)

  Range

30–76

36–69

  1. Data are mean (standard deviation [SD]) unless indicated otherwise.
  2. ABC-CFX, Aberrant Behavior Checklist – Community edition using the FXS specific algorithm; BMI, body mass index; CGI-S, Clinical Global Impression – Severity scale; IQ, Intelligence Quotient.
Back to article page